Exelixis, Inc. (EXEL): Price and Financial Metrics

Exelixis, Inc. (EXEL): $23.97

0.16 (+0.67%)

POWR Rating

Component Grades













Add EXEL to Watchlist
Sign Up

Industry: Biotech


of 492

in industry


  • Value is the dimension where EXEL ranks best; there it ranks ahead of 96.03% of US stocks.
  • EXEL's strongest trending metric is Stability; it's been moving up over the last 198 days.
  • EXEL ranks lowest in Growth; there it ranks in the 10th percentile.

EXEL Stock Summary

  • The ratio of debt to operating expenses for Exelixis Inc is higher than it is for about only 9.06% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.13 for Exelixis Inc; that's greater than it is for just 9.56% of US stocks.
  • In terms of volatility of its share price, EXEL is more volatile than merely 10.99% of stocks we're observing.
  • Stocks that are quantitatively similar to EXEL, based on their financial statements, market capitalization, and price volatility, are CRUS, MITK, FORM, SSTK, and KTOS.
  • Visit EXEL's SEC page to see the company's official filings. To visit the company's web site, go to www.exelixis.com.

EXEL Price Target

For more insight on analysts targets of EXEL, see our EXEL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $31.29 Average Broker Recommendation 1.43 (Moderate Buy)

EXEL Stock Price Chart Interactive Chart >

Price chart for EXEL

EXEL Price/Volume Stats

Current price $23.97 52-week high $27.80
Prev. close $23.81 52-week low $18.18
Day low $23.76 Volume 2,201,600
Day high $24.43 Avg. volume 2,035,839
50-day MA $23.22 Dividend yield N/A
200-day MA $22.37 Market Cap 7.50B

Exelixis, Inc. (EXEL) Company Bio

Exelixis is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. The company was founded in 1994 and is based in San Francisco, California.

EXEL Latest News Stream

Event/Time News Detail
Loading, please wait...

EXEL Latest Social Stream

Loading social stream, please wait...

View Full EXEL Social Stream

Latest EXEL News From Around the Web

Below are the latest news stories about Exelixis Inc that investors may wish to consider to help them evaluate EXEL as an investment opportunity.

Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May

Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will participate in fireside chats at the following virtual investor conferences in May:

Yahoo | April 27, 2021

Is EXEL Stock A Buy or Sell?

Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock […]

Yahoo | April 26, 2021

3 Top Biotech Picks to Buy and Hold for the Next 10 Years

Vertex Pharmaceuticals (NASDAQ: VRTX) is a giant in the cystic fibrosis (CF) market. The company sells four CF drugs. The company's pipeline includes candidates for pain, blood disorders, and type 1 diabetes, among other illnesses.

Yahoo | April 25, 2021

Exelixis, Inc.'s (NASDAQ:EXEL) Stock Is Going Strong: Have Financials A Role To Play?

Exelixis' (NASDAQ:EXEL) stock is up by a considerable 12% over the past month. Given that stock prices are usually...

Yahoo | April 24, 2021

3 Growth Stocks That'll Make You Richer in Q2 (and Beyond)

Over the long run, value stocks have outperformed growth stocks on an annualized basis. Historically low lending rates and a highly accommodative Federal Reserve have rolled out the red carpet for fast-growing companies looking to borrow at extremely cheap rates. As we move headlong into the second quarter, the following three growth stocks stand out for having all the tools needed to make investors a lot richer.

Yahoo | April 8, 2021

Read More 'EXEL' Stories Here

EXEL Price Returns

1-mo 2.74%
3-mo 3.45%
6-mo 15.74%
1-year -8.48%
3-year 7.92%
5-year 400.42%
YTD 19.43%
2020 13.90%
2019 -10.42%
2018 -35.30%
2017 103.89%
2016 164.36%

Continue Researching EXEL

Here are a few links from around the web to help you further your research on Exelixis Inc's stock as an investment opportunity:

Exelixis Inc (EXEL) Stock Price | Nasdaq
Exelixis Inc (EXEL) Stock Quote, History and News - Yahoo Finance
Exelixis Inc (EXEL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7568 seconds.